Ikaria, NuPathe File Initial Public Offerings
This article was originally published in The Pink Sheet Daily
Weak performance by a smattering of biotechs that went public in early 2010 hasn't deterred two more from being first to register this year.
You may also be interested in...
Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.
Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range
$15 million will be used to pay debt to Australian drug maker pSivida, which gave Alimera its lead compound.
Ikaria Backers Buy INO, Create Model for Self-Funding Discovery
Ikaria's private-equity funded acquisition of INO Therapeutics will allow the company to self-fund its continuing discovery programs while acting as a magnet for additional external commercial or clinical stage projects.